Validations Queue

108,318 candidate doc → node links pending adjudication. Each was auto-generated by cosine similarity ≥ 0.55 between document and prediction embeddings (bge-base-en-v1.5, 768-dim). Showing page 20 of 87, 50 rows by similarity. Adjudicating updates doc_node_links.reviewed=true with the chosen polarity, writes per-link rows to audit_log, and removes the row from this queue. Phase 4 inference will use confirmed corroborates/contradicts links as Bayesian evidence.

Pending (total)

108,318

Reviewed

Filtered

4,344

page 20 / 87

Showing on page

Filters

URL params control source + min-similarity threshold

Source

All (108318)arxiv (50087)codex_research_pack (134)edgar_8k (3666)fda (5175)gdelt (1218)github_release (3337)manifold (10773)polymarket (33928)

Page size

50 100 200 500

Bulk auto-confirm by similarity threshold

Confirm or label (corroborates / contradicts) all unreviewed links above a similarity threshold in one transaction. Each affected row writes a per-link audit_log entry. Capped at 1,000 links per call. Use Preview first.

Threshold:Source:Action:

Source0 selected · 0 visible

Bulk action

Sim	Doc	Source	Pred	Domain	Prior
0.61	FDA BLA761055: DUPIXENT (DUPILUMAB) — REGENERON PHARMACEUTICALS	fda 2026-04-22	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA ANDA218872: LENALIDOMIDE (LENALIDOMIDE) — ACCORD HLTHCARE	fda 2026-04-27	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA ANDA211132: LEUCOVORIN CALCIUM (LEUCOVORIN CALCIUM) — INGENUS PHARMS LLC	fda 2026-05-05	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA NDA022433: BRILINTA (TICAGRELOR) — ASTRAZENECA	fda 2026-05-07	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA BLA761070: FASENRA (BENRALIZUMAB) — ASTRAZENECA AB	fda 2026-05-13	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA ANDA219722: L-GLUTAMINE (L-GLUTAMINE) — ANNORA PHARMA	fda 2026-05-26	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA ANDA220041: TOPIRAMATE (TOPIRAMATE) — RICONPHARMA LLC	fda 2026-05-26	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA ANDA077747: OXCARBAZEPINE (OXCARBAZEPINE) — RUBICON RESEARCH	fda 2026-05-15	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA BLA761354: TOFIDENCE (TOCILIZUMAB-BAVI) — BIOGEN MA	fda 2026-05-22	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA ANDA215411: SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (SITAGLIPTIN, METFORMIN HYDROCHLORIDE) — INVENTIA HEALTHCARE LIMITED	fda 2026-05-07	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA NDA021951: ABSORICA (ISOTRETINOIN) — SUN PHARM INDS INC	fda 2026-06-12	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA NDA021131: ZYVOX (LINEZOLID) — PFIZER	fda 2026-06-09	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA ANDA200343: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — GENUS	fda 2026-06-18	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA ANDA089990: ACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN) — STRIDES PHARMA INTL	fda 2026-06-18	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA ANDA204407: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — NOVEL LABS INC	fda 2026-06-18	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA ANDA209021: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — ASCENT PHARMS INC	fda 2026-06-18	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA ANDA209036: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — ABHAI LLC	fda 2026-06-18	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA ANDA087508: ACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN) — GENUS LIFESCIENCES	fda 2026-06-18	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA ANDA211690: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — SANALUZ	fda 2026-06-18	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA NDA005010: DEMEROL (MEPERIDINE HYDROCHLORIDE) — QUAGEN	fda 2026-06-18	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA ANDA080448: MEPERIDINE HYDROCHLORIDE (MEPERIDINE HYDROCHLORIDE) — SUN PHARM INDUSTRIES	fda 2026-06-18	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA ANDA203602: MORPHINE SULFATE (MORPHINE SULFATE) — NOVEL LABS INC	fda 2026-06-18	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA ANDA074278: LEVORPHANOL TARTRATE (LEVORPHANOL TARTRATE) — HIKMA	fda 2026-06-18	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA ANDA201013: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — AUROLIFE PHARMA LLC	fda 2026-06-18	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA ANDA201448: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — SANKALP LIFECARE	fda 2026-06-18	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA ANDA090733: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — PH HEALTH	fda 2026-06-18	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA NDA050817: CEFEPIME IN PLASTIC CONTAINER (CEFEPIME HYDROCHLORIDE) — BAXTER HLTHCARE	fda 2026-06-25	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA NDA210793: NUPLAZID (PIMAVANSERIN TARTRATE) — ACADIA PHARMS INC	fda 2026-04-27	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA ANDA211559: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — MACLEODS PHARMS LTD	fda 2026-04-06	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA ANDA214216: EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE (EMTRICITABINE) — MACLEODS PHARMS LTD	fda 2026-04-07	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA ANDA214055: SELEXIPAG (SELEXIPAG) — RK PHARMA	fda 2026-04-16	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA ANDA216370: LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM) — ALEMBIC	fda 2026-05-20	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA ANDA208045: LURASIDONE HYDROCHLORIDE (LURASIDONE HYDROCHLORIDE) — AUROBINDO PHARMA LTD	fda 2026-05-15	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA NDA220787: ZAYNICH (CEFEPIME HYDROCHLORIDE) — WOCKHARDT BIO AG	fda 2026-05-29	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA ANDA207137: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — AMNEAL PHARMS	fda 2026-06-18	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA ANDA091440: LEVONORGESTREL AND ETHINYL ESTRADIOL (ETHINYL ESTRADIOL) — LUPIN LTD	fda 2026-06-16	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA ANDA207574: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — SANALUZ	fda 2026-06-18	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA ANDA206869: HYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — AMNEAL PHARMS NY	fda 2026-06-18	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA ANDA206136: PIROXICAM (PIROXICAM) — STRIDES PHARMA	fda 2026-06-25	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA ANDA204752: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — NOVEL LABS INC	fda 2026-06-18	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA ANDA218740: CETRORELIX ACETATE (CETRORELIX ACETATE) — HUMANWELL	fda 2026-04-29	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA ANDA076780: ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE (ONDANSETRON HYDROCHLORIDE) — HIKMA FARMACEUTICA	fda 2026-04-08	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA NDA018900: METRO I.V. IN PLASTIC CONTAINER (METRONIDAZOLE) — B BRAUN	fda 2026-04-23	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA ANDA211491: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN) — SUN PHARM	fda 2026-05-21	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA ANDA218093: FLECAINIDE ACETATE (FLECAINIDE ACETATE) — OMSAV PHARMA	fda 2026-04-22	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%
0.61	FDA ANDA075435: GABAPENTIN (GABAPENTIN) — TEVA PHARMS	fda 2026-05-07	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA NDA219531: SDAMLO (AMLODIPINE BESYLATE) — BRILLIAN PHARMA	fda 2026-05-08	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA ANDA220717: ZOLPIDEM TARTRATE (ZOLPIDEM TARTRATE) — UMEDICA LABS PVT	fda 2026-05-12	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA ANDA078479: BRIMONIDINE TARTRATE (BRIMONIDINE TARTRATE) — APOTEX	fda 2026-05-20	242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross	Biotech/Longevity	31%
0.61	FDA ANDA218088: REVEFENACIN (REVEFENACIN) — LUPIN INC.	fda 2026-05-15	COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack	Biotech/Longevity	47%